通过抑制DNA损伤反应,FASN抑制提高了结肠直肠癌化疗的有效性
Moumita Banerjee1, Yekaterina Y Zaytseva1, Ellen M Reusch1
1University of Kentucky Lexington, KY United States.
Cancer research
|February 9, 2026
概括
脂肪酸合成酶 (FASN) 在结肠直肠癌 (CRC) 中的抑制会导致DNA损伤和损害修复. 将FASN抑制剂与化疗和PARP抑制剂结合起来,为预防瘤复发提供了一个有希望的策略.
科学领域:
- 在瘤学瘤学.
- 癌症新陈代谢 癌症新陈代谢
- 对DNA损伤的反应反应
背景情况:
- 改变的脂质代谢,特别是由脂肪酸合成酶 (FASN) 调节的新型脂质生成,是结肠直肠癌 (CRC) 的代谢脆弱性.
- 单独使用FASN抑制剂的疗效很小,因此需要结合策略来改善患者的存活率.
- 了解FASN抑制对DNA损伤和修复的影响对于开发有效的CRC疗法至关重要.
研究的目的:
- 研究FASN抑制对DNA损伤和结直肠癌中DNA损伤反应 (DDR) 的影响.
- 探索涉及FASN抑制剂,化疗和PARP抑制剂用于CRC治疗的组合策略.
- 为了阐明FASN抑制诱导的PARP抑制剂合成致死性的机制基础.
主要方法:
- 来自TVB-2640窗口试验的患者样本的分析.
- 使用结肠癌细胞系和患者衍生器官的体外研究.
- 评估DNA损伤 (DSBs),亡,基因素乙化,ATM表达,CHK2酸化和BRCA1/ATM对g-H2AX焦点的招募.
- 在异种移植模型中对组合疗法的评估.
主要成果:
- 抑制FASN诱导DNA损伤,但损害了CRC细胞和有机体中的DNA损伤反应 (DDR).
- 通过改变基因组乙化,FASN抑制增强了化疗诱导的双链DNA断裂 (DSB) 和亡.
- 通过减少ATM表达和CHK2酸化,FASN抑制阻断了DDR,并减弱了BRCA1/ATM对g-H2AX焦点的招募.
- 抑制FASN诱导合成致命性与抑制PARP.
- 结合FASN抑制与伊利诺特干,在体内协同减少瘤生长和复发,通过维持olaparib进一步增强.
结论:
- 在结直肠癌中,FASN抑制会损害DNA修复机制.
- 将FASN抑制剂与化疗和PARP抑制剂相结合,代表了一种可行的治疗策略,以克服治疗耐药性并预防CRC中的瘤复发.
- 这种方法有可能改善结直肠癌患者的长期存活率.
相关概念视频
00:46Feedback Inhibition
57.3K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.3K
01:30Enzyme Inhibition
92.8K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.8K
02:34Inhibition of Cdk Activity
6.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
02:36DNA Damage Can Stall the Cell Cycle
3.2K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.2K
02:36DNA Damage can Stall the Cell Cycle
10.2K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.2K
01:22Dose-Response Relationship: Potency and Efficacy
6.6K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.6K